Floatz logo

FLUOROURACILUM

Acute Myeloid Leukemia

IGM Biosciences, Inc.Small moleculePhase 1Dormant
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
59/ 100

Competitive context

374 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Daunorubicin
Shen yang
Phase 4BB
Idarubicine
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
ETOPOSIDE
Memorial Sloan Kettering Cancer Center
Phase 4BB
Mitoxantrone
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
FILGRASTIM
City of Hope Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →